Cargando…

Safety and Efficacy of Fingolimod and Natalizumab in Multiple Sclerosis After the Failure of First-Line Therapy: Single Center Experience Based on the Treatment of Forty-Four Patients

BACKGROUND: In Poland, natalizumab or fingolimod treatment can be delivered as a second-line therapy to those patients with relapsing-remitting multiple sclerosis (RRMS) who demonstrated no response to interferon or glatiramer acetate treatment for a minimum of one year. The objective of this study...

Descripción completa

Detalles Bibliográficos
Autores principales:	Puz, Przemysław, Lasek-Bal, Anetta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Scientific Literature, Inc. 2016
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5115216/ https://www.ncbi.nlm.nih.gov/pubmed/27829656 http://dx.doi.org/10.12659/MSM.898270

Ejemplares similares

Modified Rio Score with Platform Therapy Predicts Treatment Success with Fingolimod and Natalizumab in Relapsing-Remitting Multiple Sclerosis Patients
por: Jamroz-Wiśniewska, Anna, et al.
Publicado: (2021)

Patent foramen ovale and cryptogenic stroke – a statistical or cause-and-effect relationship? A neurological point of view
por: Lasek-Bal, Anetta, et al.
Publicado: (2013)

Elevated factor VIII level and stroke in patients without traditional risk factors associated with cardiovascular diseases
por: Anetta, Lasek-Bal, et al.
Publicado: (2013)

Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment
por: Vollmer, Brandi L., et al.
Publicado: (2018)

Inflammatory markers in patients with internal carotid artery stenosis
por: Puz, Przemysław, et al.
Publicado: (2013)

Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment
por: Vollmer, Brandi L., et al.
Publicado: (2020)

Ocrelizumab versus fingolimod after natalizumab cessation in multiple sclerosis: an observational study
por: Bigaut, Kévin, et al.
Publicado: (2022)

Complex interventional treatment in a patient with atrial fibrillation and stroke caused by large carotid artery thrombus: a case report
por: Lasek-Bal, Anetta, et al.
Publicado: (2015)

Prognostic Role of Chronic Rhinosinusitis in Acute Ischemic Stroke Patients Undergoing Mechanical Thrombectomy
por: Puz, Przemysław, et al.
Publicado: (2021)

Clinical and Non-Clinical Determinants of the Effect of Mechanical Thrombectomy and Post-Stroke Functional Status of Patients in Short and Long-Term Follow-Up
por: Lasek-Bal, Anetta, et al.
Publicado: (2021)

Comparison of Dimethyl Fumarate vs Fingolimod and Rituximab vs Natalizumab for Treatment of Multiple Sclerosis
por: Hou, Jue, et al.
Publicado: (2021)

Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
por: Grahl, S., et al.
Publicado: (2021)

Second line use of Fingolimod is as effective as Natalizumab in a German out-patient RRMS-cohort
por: Braune, Stefan, et al.
Publicado: (2013)

PML-IRIS during Fingolimod Diagnosed after Natalizumab Discontinuation
por: Killestein, J., et al.
Publicado: (2014)

Progressive Multifocal Leukoencephalopathy in a Multiple Sclerosis Patient Diagnosed after Switching from Natalizumab to Fingolimod
por: Sinnecker, Tim, et al.
Publicado: (2016)

Effect of Rituximab Compared with Natalizumab and Fingolimod in Patients with Relapsing–Remitting Multiple Sclerosis: A Cohort Study
por: Hernández-Preciado, Martha Rocio, et al.
Publicado: (2022)

Cerebral microembolism during atrial fibrillation ablation can result from the technical aspects and mostly does not cause permanent neurological deficit
por: Lasek-Bal, Anetta, et al.
Publicado: (2020)

Plasma Levels of Occludin and Claudin-5 in Acute Stroke Are Correlated with the Type and Location of Stroke but Not with the Neurological State of Patients—Preliminary Data
por: Lasek-Bal, Anetta, et al.
Publicado: (2020)

Interferon-Beta Increases Plasma Ceramides of Specific Chain Length in Multiple Sclerosis Patients, Unlike Fingolimod or Natalizumab
por: Ottenlinger, Florian M., et al.
Publicado: (2016)

NEDA-3 status including cortical lesions in the comparative evaluation of natalizumab versus fingolimod efficacy in multiple sclerosis
por: Puthenparampil, Marco, et al.
Publicado: (2018)

Safety of Fingolimod in Patients with Multiple Sclerosis Switched from Natalizumab: Results from TRANSITION―A 2-Year, Multicenter, Observational, Cohort Study
por: Butzkueven, Helmut, et al.
Publicado: (2022)

Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis
por: Lefort, M., et al.
Publicado: (2022)

Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study
por: Barbin, Laetitia, et al.
Publicado: (2016)

Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS
por: Kappos, Ludwig, et al.
Publicado: (2015)

Long-term evaluation of NEDA-3 status in relapsing-remitting multiple sclerosis patients after switching from natalizumab to fingolimod
por: Diem, Lara, et al.
Publicado: (2018)

Long-Term Efficacy Outcomes of Natalizumab vs. Fingolimod in Patients With Highly Active Relapsing-Remitting Multiple Sclerosis: Real-World Data From a Multiple Sclerosis Reference Center
por: Boziki, Marina, et al.
Publicado: (2021)

Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial
por: Laroni, Alice, et al.
Publicado: (2014)

Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients
por: Leurs, Cyra E, et al.
Publicado: (2017)

Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor)
por: Klotz, Luisa, et al.
Publicado: (2015)

Permeability of the blood–brain barrier predicts no evidence of disease activity at 2 years after natalizumab or fingolimod treatment in relapsing–remitting multiple sclerosis
por: Cramer, Stig P., et al.
Publicado: (2018)

Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study
por: Butzkueven, Helmut, et al.
Publicado: (2020)

Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom
por: Spelman, Timothy, et al.
Publicado: (2021)

Interferons and Natalizumab for Multiple Sclerosis
por: Clar, Christine, et al.
Publicado: (2008)

Natalizumab in the treatment of multiple sclerosis
por: Brown, Brandon A
Publicado: (2009)

The use of natalizumab for multiple sclerosis
por: Brandstadter, Rachel, et al.
Publicado: (2017)

Natalizumab Rebound in Multiple Sclerosis
por: Lee, Joshua D., et al.
Publicado: (2021)

Four-year safety and effectiveness data from patients with multiple sclerosis treated with fingolimod: The Spanish GILENYA registry
por: Meca-Lallana, J. E., et al.
Publicado: (2021)

The Association of SNPs Located in the CDKN2B-AS1 and LPA Genes With Carotid Artery Stenosis and Atherogenic Stroke
por: Lasek-Bal, Anetta, et al.
Publicado: (2019)

Safety and Efficacy of Fingolimod in Treatment-Naïve Multiple Sclerosis Patients
por: Marriott, James J.
Publicado: (2011)

Annualized hospitalization rate with natalizumab vs fingolimod in second-line treatment for RRMS in the public healthcare system in Brazil: A claim database approach
por: Julian, Guilherme Silva, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_39hf8b4k3624stkgce20h7oo4d